Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Category: Pharma Industry
The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract [...] …
Federal regulators last Friday finalized a highly anticipated rule for the Medicaid Drug Rebate Program (MDRP) with new identifiers and [...] …
A major drug industry trade group and the federal government have asked a federal judge to continue to pause litigation [...] …
An influential Republican senator this morning requested detailed information from Eli Lilly and Amgen on their 340B programs, including the [...] …
The federal government’s recent threat to penalize Johnson & Johnson (J&J) for its unapproved 340B rebate model could spark a [...] …
A federal district judge ruled that four drugmakers’ 340B contract pharmacy restrictions—as implemented in 2021—do not violate the 340B statute, [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
The federal agency that oversees the 340B program today formally warned Johnson & Johnson (J&J) that it must “cease implementation [...] …
The sponsor of new Senate legislation that would codify providers’ ability to use contract pharmacies to dispense 340B discounted drugs [...] …